
This builds on a recently announced clinical collaboration between AstraZeneca and Summit to advance cancer treatments

As the oncology landscape continues to evolve, life sciences organizations face a growing challenge: how do you communicate increasingly complex science in a way that creates meaningful engagement?

Exploring how empathetic, patient-centred communication can make planned treatment breaks easier to discuss as part of cancer care.

Following ASCO® 2026, Inizio's experts have shared their perspectives across three thought leadership articles, each exploring a different aspect of what this year's congress revealed for pharmaceutical organisations. Together, they...

The unique combination of technology marks 25 years of industry innovation and expertise, and signals company’s next phase of business growth and client value

Key insights from ASCO® 2026, including oncology trends, scientific highlights, and strategies for smarter congress engagement.

The companies plan to research and develop 12 new cancer treatments

In healthcare, disengagement rarely announces itself. It doesn’t always appear as refusal or a clear decision to stop treatment. More often, it shows up quietly, in what is delayed, avoided...

The treatment is currently being evaluated in a phase 1/2 multicentre clinical study

The acquisition builds on Gilead’s oncology pipeline, focused on addressing areas of high unmet need

Healthcare Research Worldwide (HRW) has been named a winner in the 2026 Artificial Intelligence Excellence Awards in the Pharmaceutical category, recognizing its innovative use of AI to deliver real-world impact....

The new programme addresses the urgent unmet medical need for new therapies to tackle antibiotic-resistant infections